CPH
Physician Daily · Monday, August 24, 2026
Newsletters Sign in ON AIR
CrosspointHealthNEWS + REFERENCE LIBRARY
Diagnosis Sheet Substance-Related and Addictive Disorders DSM-5-TR 291.81 | ICD-10-CM F10.239, F10.232

Alcohol Withdrawal

GABA-glutamate rebound after cessation in a dependent drinker, spanning tremor to withdrawal seizures and delirium tremens.

Symptom onset6-24 hr after last drink
Withdrawal seizures~10% of AWS; 12-48 hr
Delirium tremens~3-5% of AWS; 48-96 hr
DT mortality~15-20% untreated; <5% treated

Clinical picture

  • Autonomic hyperactivity begins 6 to 24 hours after the last drink: tremor, diaphoresis, tachycardia, hypertension, nausea, anxiety, and insomnia.
  • Withdrawal seizures are generalized tonic-clonic, usually single or in a brief cluster, and peak between 12 and 48 hours after cessation.
  • Alcoholic hallucinosis appears at 12 to 24 hours with vivid visual or tactile hallucinations, a clear sensorium, and preserved orientation.
  • Delirium tremens emerges at 48 to 96 hours with clouded consciousness, disorientation, severe agitation, fever, and full autonomic storm.
  • Severity worsens with each prior detoxification through kindling, so a history of past withdrawals predicts course better than reported intake.
  • Occult trauma, infection, pancreatitis, GI bleeding, and hepatic encephalopathy frequently coexist and can mimic or amplify withdrawal.

Criteria snapshot

  • Requires cessation or reduction of heavy, prolonged alcohol use followed by at least 2 of 8 characteristic signs within hours to a few days.
  • The eight signs are autonomic hyperactivity, hand tremor, insomnia, nausea or vomiting, transient hallucinations or illusions, psychomotor agitation, anxiety, and seizures.
  • Symptoms must cause significant distress or impairment and must not be attributable to another medical condition or to another substance.
  • The specifier with perceptual disturbances applies when hallucinations or illusions occur with intact reality testing and a clear sensorium.
  • Delirium tremens is coded separately as alcohol withdrawal delirium, which additionally requires disturbed attention and awareness.

Neurobiology

  • Chronic alcohol downregulates GABA-A receptors and upregulates NMDA receptors; abrupt cessation leaves unopposed glutamatergic excitation.
  • Sympathetic outflow surges as alpha-2 autoreceptor inhibition is lost, producing tachycardia, hypertension, tremor, and diaphoresis.
  • Kindling from repeated withdrawal episodes progressively lowers seizure threshold through limbic sensitization, so each detox is more dangerous.
  • Hypomagnesemia, hypokalemia, hypophosphatemia, and hypoglycemia are near-universal and independently lower the seizure threshold further.
  • Thiamine stores deplete within 2 to 3 weeks of poor intake, and a glucose load given without thiamine can precipitate Wernicke encephalopathy.
  • The Wernicke triad of confusion, ophthalmoplegia, and ataxia is complete in fewer than 20% of cases, so treat empirically on suspicion alone.

Psychology

  • Fear of withdrawal itself is a major driver of continued drinking and of premature self-discharge from medical detoxification.
  • Anxiety, insomnia, and dysphoria persist for weeks as protracted withdrawal and strongly predict early relapse if left unaddressed.
  • Conditioned withdrawal responses can be triggered by drinking cues alone, producing craving that convincingly mimics physiologic symptoms.
  • Detoxification is not treatment; without immediate linkage to ongoing care, relapse after medical withdrawal alone exceeds 70%.
  • Shame and prior negative experiences in emergency settings reduce honest disclosure of intake, so corroborate the history when possible.

Differential & comorbidity

  • Score severity with the 10-item CIWA-Ar (maximum 67): under 8 is mild, 8 to 15 moderate, and above 15 severe with high complication risk.
  • Exclude sepsis, meningitis, subdural hematoma, thyrotoxicosis, hepatic encephalopathy, anticholinergic toxicity, and sedative-hypnotic withdrawal.
  • CIWA-Ar is invalid in intubated, delirious, or non-communicating patients; use RASS with objective vital signs in those settings instead.
  • Predict risk prospectively with the PAWSS: a score of 4 or more identifies patients who need prophylactic medication for complicated withdrawal.
  • Delirium tremens risk factors: prior DTs or withdrawal seizure, CIWA-Ar above 15, systolic BP above 150, concurrent infection, and heavy daily intake.

Pharmacologic treatment

  • Benzodiazepines are the only class proven to reduce withdrawal seizures and delirium; every other agent is adjunctive, never a substitute.
  • Symptom-triggered dosing when CIWA-Ar exceeds 8 to 10 lowers total benzodiazepine exposure and shortens treatment versus fixed schedules.
  • Fixed-schedule chlordiazepoxide 50-100 mg every 6 hours tapered over 3 to 5 days suits unmonitored settings and prior complicated withdrawal.
  • Front-loading diazepam 10-20 mg every 1 to 2 hours to light sedation exploits active metabolites to produce a self-tapering course.
  • Give thiamine 100-500 mg IV before any dextrose, and use lorazepam 1-4 mg in cirrhosis, advanced age, or respiratory compromise.

Psychotherapy

  • Withdrawal management alone does not treat alcohol use disorder; begin motivational interviewing during the medicated phase itself.
  • CBT with relapse prevention started on the inpatient unit and continued in outpatient care improves 12-month abstinence rates.
  • Brief interventions of 1 to 4 sessions during the hospital stay increase treatment entry and reduce subsequent drinking quantity.
  • A warm handoff to a scheduled outpatient appointment within 72 hours of discharge outperforms a referral slip by a very wide margin.
  • Twelve-step facilitation begun during the admission raises mutual-help attendance after discharge and supports early abstinence.

Adjunct options

  • Phenobarbital 10-15 mg/kg loading is used for benzodiazepine-refractory withdrawal and increasingly as monotherapy in emergency settings.
  • Refractory delirium tremens needs ICU care with dexmedetomidine or propofol infusion alongside continued benzodiazepines and airway control.
  • Beta blockers and clonidine blunt autonomic signs but mask CIWA-Ar scores and do not prevent seizures or delirium on their own.
  • Admit for prior DTs or withdrawal seizure, PAWSS of 4 or more, unstable medical or psychiatric comorbidity, pregnancy, or no sober support.
  • Correct magnesium, potassium, phosphate, and folate; check glucose, LFTs, lipase, CBC, and head CT when trauma or focal signs are present.

Clinical pearls

  • Thiamine before glucose, always: dextrose first can precipitate Wernicke encephalopathy.
  • Kindling means each prior detox raises seizure and DT risk; count past withdrawals.
  • Untreated delirium tremens kills 15-20%; treated, under 5%. It is an emergency.

References

  • Amato, L., Minozzi, S., Vecchi, S., & Davoli, M. (2010). Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews, 2010(3), CD005063. https://doi.org/10.1002/14651858.CD005063.pub3
  • American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
  • American Society of Addiction Medicine. (2020). The ASAM clinical practice guideline on alcohol withdrawal management. Journal of Addiction Medicine, 14(3S), 1-72. https://doi.org/10.1097/ADM.0000000000000668
  • Canver, B. R., Newman, R. K., & Gomez, A. E. (2024). Alcohol withdrawal syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441882/
  • Mayo-Smith, M. F. (1997). Pharmacological management of alcohol withdrawal: A meta-analysis and evidence-based practice guideline. JAMA, 278(2), 144-151. https://doi.org/10.1001/jama.1997.03550020076042
  • Saitz, R., Mayo-Smith, M. F., Roberts, M. S., Redmond, H. A., Bernard, D. R., & Calkins, D. R. (1994). Individualized treatment for alcohol withdrawal: A randomized double-blind controlled trial. JAMA, 272(7), 519-523. https://doi.org/10.1001/jama.1994.03520070039035
  • Schuckit, M. A. (2014). Recognition and management of withdrawal delirium (delirium tremens). New England Journal of Medicine, 371(22), 2109-2113. https://doi.org/10.1056/NEJMra1407298
  • Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A., & Sellers, E. M. (1989). Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction, 84(11), 1353-1357. https://doi.org/10.1111/j.1360-0443.1989.tb00737.x